ClinicalTrials.gg
Sign In

Urethral Neoplasms clinical trials

The registry lists 95 studies for Urethral Neoplasms across more than 10 countries. 5 are recruiting or about to start. 5 of them are mainly about Urethral Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Urethral Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
63
Active, not recruiting
14
Terminated
9
Recruiting
5
Status unknown
3
Withdrawn
1

Phase

Phase 2
58
Phase 1
24
Phase 3
9
Early Phase 1
1

Where

United States
76
United Kingdom
11
Spain
10
Canada
10
Italy
8
France
8

Who runs them

National Cancer Institute (NCI) (19) · M.D. Anderson Cancer Center (9) · Eastern Cooperative Oncology Group (6) · SWOG Cancer Research Network (6) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Eli Lilly and Company (3) · Cardiff University (3) · Emory University (2)

What is being tested here

Drugs under test in Urethral Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cabozantinib114
Nivolumab104
Ipilimumab102
Tamibarotene101
Gemcitabine0220
Cisplatin0211
Paclitaxel0310
Carboplatin036
Doxorubicin015
Fluorouracil004

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Immune checkpoint inhibitors 1 open · Antimetabolites 26 · Antimitotic agents 19 · Angiogenesis inhibitors 10

Coming up

1phase 3 study under way
9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Who these studies take

Of the 5 Urethral Neoplasms studies recruiting now, 2 (40%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
100 (0%)0 (0%)
184 (80%)4 (80%)
305 (100%)5 (100%)
405 (100%)5 (100%)
505 (100%)5 (100%)
655 (100%)5 (100%)
755 (100%)5 (100%)
854 (80%)4 (80%)

Across all 95 studies, recruiting or not: 1% stop at 75 or younger and 0% at 65; 13% take children; 0% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urethral Neoplasms studies take

Of 20 phase 2 interventional studies under Urethral Neoplasms, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 251 mo36–132 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 95. Browse all 95 → or search them.